Why the study?
Can circulating microRNAs serve as potential noninvasive biomarkers for atrial fibrillation?
Can circulating microRNAs serve as potential noninvasive biomarkers for atrial fibrillation?
This review highlights the potential of circulating microRNAs as noninvasive biomarkers for atrial fibrillation while noting the variability in current study results.
MicroRNA profiling warrants further study as an AF biomarker; leaves open standardization and validation for clinical use.
Atrial fibrillation (AF) is the most common supraventricular arrhythmia in the population. MicroRNAs (small endogenous noncoding RNAs) are attractive candidates as biomarkers for AF, especially considering that miRNAs are stable and are detected within easily accessible biofluids such as blood. In this review, we selected twelve studies (2012 to 2016) that were classified according to the sample type. We aimed to provide an overview of the role of circulating miRNAs in AF and to discuss the variability of the results, seeking to improve the perspective of the use of miRNAs as potential noninvasive biomarkers for this heart disease.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: